Fish Oil Derivatives in Hypertriglyceridemia: Mechanism and Cardiovascular Prevention: What do studies say?
Publication/Presentation Date
8-30-2023
Abstract
Hypertriglyceridemia is a type of dyslipidemia characterized by high triglyceride levels in the blood and increases the risk of cardiovascular disease. Conventional management includes antilipidemic medications such as statins, lowering LDL and triglyceride levels as well as raising HDL levels. However, the treatment may be stratified using omega-3 fatty acid supplements such as eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA), aka fish oil derivatives. Studies have shown that fish oil supplements reduce risk of cardiovascular diseases; however, the underlying mechanism and the extent of reduction in CVD needs more clarification. Our paper aims to review the clinical trials and observational studies in the current literature, investigating the use of fish oil and its benefits on cardiovascular system as well as the proposed underlying mechanism.
First Page
102066
Last Page
102066
ISSN
1535-6280
Published In/Presented At
Erbay, M. I., Gamarra, N. N., Patel, P., Ozkan, H. S., Wilson, A., Banerjee, S., Babazade, A., Londono, V., Sood, A., & Gupta, R. (2023). Fish Oil Derivatives in Hypertriglyceridemia: Mechanism and Cardiovascular Prevention: What do studies say?. Current problems in cardiology, 102066. Advance online publication. https://doi.org/10.1016/j.cpcardiol.2023.102066
Disciplines
Medicine and Health Sciences
PubMedID
37657524
Department(s)
Department of Medicine, Cardiology Division, Department of Medicine Fellows and Residents, Fellows and Residents
Document Type
Article